Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 800 results for "gilead sciences"

Gilead Is on the Verge of a Breakout

Gilead Is on the Verge of a Breakout

Gilead Sciences (GILD - Get Report) has been battling heavy resistance near its 200-day moving average since the middle of last week. The stock has remained in a tight range during this struggle, but that may soon change. As Wednesday came to a ..., 1 day ago
Medical News Today

Gilead Sciences passes EC marketing approval for once-daily single tablet regimen Genvoya for treating HIV-1 infection in all 28 countries of the EU

Biopharmaceutical company Gilead Sciences (NasdaqGS:GILD) said on Monday that it has received European Commission (EC) marketing approval for once-daily single tablet regimen Genvoya (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 ...
 Bloomberg4 days ago Gilead Sciences to Present at Two Upcoming Investor Conferences on Tuesday, December 1  Industrial Info Financials4 days ago Gilead's Genvoya approved in Europe23-11-2015  Pharma Letter4 days ago Gilead's Genvoya cleared in Europe  Seeking Alpha5 days ago
Motley Fool

Will Merck & Co. Be the One to Finally Take Down Gilead?

Life Sciences Jobs About a year ago, while we were still waiting for Viekira Pak from AbbVie to hit pharmacy shelves, many Gilead Sciences (NASDAQ:GILD) investors were worried the competitor would consume a hefty chunk of the overall hepatitis C ...
 BioSpace4 days ago Will Merck & Co. (MRK) Be the One to Finally Take Down Gilead (GILD)? 11/24/2015  ClinicSpace4 days ago Can Merck & Co. Take Down Gilead Sciences?  Motley Fool5 days ago Gilead Sciences, Inc Still Outperforms Merck & Co And AbbVie  Bidness Etc1 week ago
Motley Fool

Gilead Sciences Grabs 4 Regulatory Wins -- but Does It Matter?

Image source: Images_of_Money via Flickr Creative Commons. Biotech blue-chip Gilead Sciences ( NASDAQ:GILD ) has been in the news a lot recently. The company is continuing to make clinical and regulatory progress on its huge pipeline, and with a ...
 Motley Fool2 days ago

Anthem Blue Cross of California sued over hepatitis C drug coverage

Nov 25 - Anthem Blue Cross of California has been hit with a class action accusing it of refusing to cover Gilead Sciences Inc's pricy hepatitis C drug Harvoni in cases where it is medically necessary. The lawsuit was filed Nov. 19 in Los ...
 Reuters2 days ago
Bidness Etc

Gilead Sciences: HCV And HIV Revenue Stream Not About To Dry Up

Gilead Sciences Inc. ( NASDAQ:GILD ) is still leading the HCV and HIV race despite tough competition from formidable rivals as well as new entrants in the space. It has two blockbuster drugs in its HCV portfolio and as many as four blockbuster ...
 Bidness Etc5 days ago

Gilead Sciences Inc. Has Plenty of Room to Run in Hepatitis C

Gilead Sciences ( NASDAQ:GILD ) has had a massively successful run with its hepatitis C cures Sovaldi and Harvoni, and the more I look at the market size and the company's treatment strategy, the more I become convinced this business has plenty of ...
 Motley Fool1 week ago
Bidness Etc

Gilead Sciences: New Script Data Add To A Great Month For HCV

The last few weeks have been encouraging for Gilead Sciences, Inc. ( NASDAQ:GILD ) in terms of its core hepatitis C franchise. The biotech giant's recent developments in HCV were rounded up well with new IMS prescription data for Harvoni and ...
 Bidness Etc1 week ago

Spring Bank Pharmaceuticals Announces Clinical Trial Collaboration with Gilead Sciences for Hepatitis B HBV Phase 2 Clinical Trial

By a News Reporter-Staff News Editor at Biotech Week -- Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, announced a clinical trial collaboration with ...
 4 Traders3 days ago X-Rx Announces Autotaxin Inhibitor Collaboration with Gilead Sciences  Pharmacy Choice3 days ago 11/25/15 - U.S. FDA Approves New Indications for HarvoniĀ®, Gilead's Once-Daily Single Tablet Regimen for Chronic Hepatitis C  Pharmacy Choice3 days ago Spring Bank partners with Gilead Sciences for Hepatitis B Phase 2 clinical trial  Pharmaceutical Business Review1 week ago
Bidness Etc

Gilead's (GILD) Cocktail HIV Drug Genvoya Approved in EU

Gilead Sciences, Inc. GILD announced that its tenofoviralafenamide (TAF)-based HIV drug, Genvoya, has been approved by the European Commission (EC). Genvoya, the TAF-based single-tablet regimen comprises TAF, Vitekta (elvitegravir), Tybost ...
 Zacks.com4 days ago Will Gilead Sciences, Inc Latest Approvals Help Drive Growth?  Bidness Etc1 week ago FDA Approves New Treatment for HIV  BlackAIDS.org1 week ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - gilead sciences
Get updated on latest news & your favorite topics right in your inbox!
More     Less